Laryea Daniel, Isaksson Anders, Wright Colin W, Larsson Rolf, Nygren Peter
Division of Clinical Pharmacology, Department of Medical Sciences, University Hospital, 751 85, Uppsala, Sweden.
Invest New Drugs. 2009 Oct;27(5):402-11. doi: 10.1007/s10637-008-9185-5. Epub 2008 Oct 14.
The plant derived indoloquinoline alkaloid cryptolepine was investigated for its cytotoxic properties in 12 human tumour cell lines and in primary cultures of tumour cells from patients. The fluorometric microculture cytotoxicity assay was used to assess cytotoxicity and DNA micro-array analysis to evaluate gene expression. Cryptolepine mean IC(50) in the cell line panel was 0.9 microM compared with 1.0 and 2.8 microM in haematological and solid tumour malignancies, respectively. Among patient solid tumour samples, those from breast cancer were the most sensitive and essentially as sensitive as haematological malignancies. Cryptolepine activity showed highest correlations to topoisomerase II and microtubule targeting drugs. In the cell lines cryptolepine activity was essentially unaffected by established mechanisms of drug resistance. A number of genes were identified as associated with cryptolepine activity. In conclusion, cryptolepine shows interesting in vitro cytotoxic properties and its further evaluation as an anti-cancer drug seems warranted.
对植物来源的吲哚喹啉生物碱隐丹参酮在12种人类肿瘤细胞系以及患者肿瘤细胞原代培养物中的细胞毒性特性进行了研究。采用荧光微量培养细胞毒性试验评估细胞毒性,并通过DNA微阵列分析评估基因表达。隐丹参酮在细胞系组中的平均半数抑制浓度(IC50)为0.9微摩尔,而在血液系统恶性肿瘤和实体瘤恶性肿瘤中分别为1.0微摩尔和2.8微摩尔。在患者实体瘤样本中,乳腺癌样本最为敏感,且与血液系统恶性肿瘤的敏感性基本相同。隐丹参酮的活性与拓扑异构酶II和微管靶向药物的相关性最高。在细胞系中,隐丹参酮的活性基本不受已确立的耐药机制影响。鉴定出了一些与隐丹参酮活性相关的基因。总之,隐丹参酮显示出有趣的体外细胞毒性特性,似乎有必要对其作为抗癌药物进行进一步评估。